EGFR and glioblastoma: 17-AAG sensitizes GBM cells to radiotherapy and to several chemotherapeutics, such as gefitinib (EGFR inhibitor) [127], enzaustarin (protein kinase C inhibitor) [128], LY294002 (PI3K inhibitor) [129], and DNA alkylating agents (TMZ, cisplatin) [130].